A study of the importance of psychodrama in therapeutic treatment for the handicapped. (c1982)

Melanoma is the more dangerous skin cancer, and metastatic melanoma still carries poor prognosis. Despite recent therapeutic advances, prolonged survival remains rare and research is still required. Propolis extracts from many countries have attracted a great deal of attention for their biological properties. We here investigated the ability of an ethanolic extract of Algerian propolis (EEP) to control melanoma tumour growth when given to mice bearing B16F1melanoma tumour either as preventive or as therapeutic treatment. EEP given after tumour occurrence increased mice survival (+30%) and reduced tumour growth (-75%). This was associated with a decrease of the Mitotic Index (-75%) and of Ki-67 (-50%) expression. When given either before or both before and after tumour occurrence, EEP reduced tumour growth but without prolonging mice life. Isolation of B16F1 melanoma cells from resected tumour showed that preventive and curative EEP treatments reduced invasiveness by 55% and 40% respectively compared to control. Galangin, one of the most abundant flavonoids in propolis, significantly reduced the number of melanoma cells in vitro and induced autophagy/apoptosis dose dependently. In conclusion, we showed that EEP reduced melanoma tumour progression/dissemination and could extend mice lifespan when used as therapeutic treatment. Then, EEP may help patients with melanoma when used as a complementary therapy to classical treatment for which autophagy is not contraindicated.

Download Full-text

Potential of electronic water as a therapeutic treatment for oxidative stress-related disease

Gynecology & Obstetrics Case report ◽

10.21767/2471-8165-c1-002 ◽

2018 ◽

Vol 04 ◽

Author(s):

Masahiro Onuma

Keyword(s):

Oxidative Stress ◽

Therapeutic Treatment ◽

Related Disease

Download Full-text

Therapeutic clinical trials to combat COVID-19 pandemic in India: analysis from trial registry

Journal of Basic and Clinical Physiology and Pharmacology ◽

10.1515/jbcpp-2020-0208 ◽

2020 ◽

Vol 0 (0) ◽

Author(s):

Angelika Batta ◽

Raj Khirasaria ◽

Vinod Kapoor ◽

Deepansh Varshney

Keyword(s):

Clinical Trials ◽

De Novo ◽

Treatment Options ◽

Drug Repurposing ◽

Trial Registry ◽

Therapeutic Treatment ◽

Clinical Trial Registry ◽

Clear Cut ◽

Therapeutic Trials ◽

Microsoft Office

AbstractObjectivesWith the emergence of Novel corona virus, hunt for finding a preventive and therapeutic treatment options has already begun at a rapid pace with faster clinical development programs. The present study was carried out to give an insight of therapeutic interventional trials registered under clinical trial registry of India (CTRI) for COVID-19 pandemic.MethodsAll trials registered under CTRI were evaluated using keyword “COVID” from its inception till 9th June 2020. Out of which, therapeutic interventional studies were chosen for further analysis. Following information was collected for each trial: type of therapeutic intervention (preventive/therapeutic), treatment given, no. of centers (single center/multicentric), type of institution (government/private), study design (randomized/single-blinded/double-blinded) and sponsors (Government/private). Microsoft Office Excel 2007 was used for tabulation and analysis.ResultsThe search yielded total of 205 trials, out of which, 127 (62%) trials were interventional trials. Out of these, 71 (56%) were AYUSH interventions, 36 (28.3%) tested drugs, 9 (7%) tested a nondrug intervention, rest were nutraceuticals and vaccines. About 66 (56%) were therapeutic trials. Majority were single-centered trials, i.e. 87 (73.7%). Trials were government funded in 57 (48.3%) studies. Majority were randomized controlled trials, i.e. 67 (56.8%). AYUSH preparations included AYUSH-64, Arsenic Album, SamshamaniVati etc.ConclusionsThe number of therapeutic interventional clinical trials was fair in India. A clear-cut need exists for an increase in both quantity and quality of clinical trials for COVID-19. Drug repurposing approach in all systems of medicine can facilitate prompt clinical decisions at lower costs than de novo drug development.

Download Full-text

Therapeutic Alliance in Interpreter-Mediated Psychotherapy from the Perspective of Refugee Patients: Results of Qualitative Interviews

Verhaltenstherapie ◽

10.1159/000517136 ◽

2021 ◽

pp. 1-9

Author(s):

Saskia Hanft-Robert ◽

Nadine Janis Pohontsch ◽

Cornelia Uhr ◽

Alexander Redlich ◽

Franka Metzner

Keyword(s):

Content Analysis ◽

Therapeutic Alliance ◽

Successful Treatment ◽

Qualitative Content Analysis ◽

Qualitative Interviews ◽

Therapeutic Treatment ◽

Factors Influencing ◽

Recommendations For Action ◽

Patients Perspective

Background: The therapeutic alliance is considered to be one of the most important factors of psychotherapy and is a necessary requirement for a successful treatment in interpreter-mediated psychotherapy. Patients and Methods: Using interpreter-mediated guided interviews, 10 refugee patients who experienced interpreter-mediated psychotherapy were asked about factors influencing the development of a trusting therapeutic alliance in the triad. The analysis of the interviews followed the rules of content-structuring qualitative content analysis. Results: A total of 11 factors were identified which could be assigned to the interpreter, therapist, or patient. In the analysis, the central role of the interpreter in establishing a therapeutic alliance in the triad became particularly clear. Conclusions: Consideration of the factors that, from the patients’ perspective, influence the establishment and maintenance of a trusting alliance within the triad, as well as the recommendations for action derived from this for psychotherapists and interpreters can lead to an improvement in the therapeutic treatment of refugees.

Download Full-text